Dr. Arvind Chhabra

University of Connecticut Health Center, USA

Email: [email protected]

Qualifications

Ph.D., Biotechnology, Central Drug Research Institution

M.S., Biotechnology, Guru Nanak Dev University

B.S., Biology, Rohilkhand University

Publications(Selected)

1. Chhabra, A. (2017). Derivation of Human Induced Pluripotent Stem Cell (iPSC) Lines and Mechanism of Pluripotency: Historical Perspective and Recent Advances. Stem Cell Reviews And Reports, 13(6), 757-773.
2. Chhabra, A. (2017). Inherent Immunogenicity or Lack Thereof of Pluripotent Stem Cells: Implications for Cell Replacement Therapy. Frontiers In Immunology, 8, 1-11.
3. Chhabra, A., Chen, I. P., & Batra, D. (2017). Human Dendritic Cell-Derived Induced Pluripotent Stem Cell Lines Are Not Immunogenic. Journal Of Immunology, 198(5), 1875-1886.
4. Chhabra, A., Mukherji, B., & Batra, D. (2017). Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53. Expert Opinion On Therapeutic Targets, 21(2), 117-129.
5. Chhabra, A., & Mukherji, B. (2016). Suppression of inducible CD4 regulatory cells by MHC class I-restricted human tumor epitope specific TCR engineered multifunctional. Human Immunology, 77(10), 905-911.
6. Chhabra, A., & Mukherji, B. (2013). Death Receptor-Independent Activation-Induced Cell Death in Human Melanoma Antigen-Specific MHC Class I-Restricted TCR-Engineered CD4 T Cells. Journal Of Immunology, 191(6), 3471-3477.
7. Chakraborty, N. G., Yadav, M., Dadras, S. S., et al. (2013). Analyses of T cell-mediated immune response to a human melanoma-associated antigen by the young and the elderly. Human Immunology, 74(5), 640-647.
8. Chhabra, A. (2011). TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations. Thescientificworldjournal, 11, 121-129.
9. Chhabra, A. (2010). Human Melanoma Antigen Specific MHC Class I TCR Engineered CD4 T Cells Undergo Epitope Specific AICD Through an Intrinsic Mitochondria-Centric Process that Involves JNK and p53. Journal Of Immunotherapy, 33(8), 893.
10. Chhabra, A. (2010). Generation and Functional Characterization of Breast Cancer Antigenic Epitope Specific Anti-Tumor T Cell Response. Journal Of Immunotherapy, 33(8), 893.
11. Ray, S., Chhabra, A., Chakraborty, N. G., et al. (2010). MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+T cells exhibit multifunctional effector and helper responses, in vitro. Clinical Immunology, 136(3), 338-347.
12. Chhabra, A. (2010). Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy. Vaccine, 28(29), 4566-4572.
13. Ray, S., Chhabra, A., Chakraborty, N. G., et al. (2010). MHC class I-restricted MART-127-35 specific TCR engineered human CD4+and CD8+T cells exhibit polyfunctional properties. Cancer Research, 70.
14. Chhabra, A., Ray, S., Chakraborty, N., et al. (2010). Activation Induced Cell Death (AICD) of Human Melanoma Antigen Specific MHC Class I TCR Engineered CD8 T Cells is an Intrinsic Process That Involves JNK and p53. Clinical Immunology, 135, S13.
15. Ray, S., Chhabra, A., Mehrotra, S., et al. (2009). Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clinics In Dermatology, 27(6), 603-613.
16. Hegde, U., Ray, S., Das, R., et al. (2009). Functional differences between induced T reg cells from tumor antigen specific CTL induction and influenza matrix antigen specific CTL induction cultures. Cancer Research, 69.
17. Chhabra, A., Ray, S., Chakraborty, N., et al. (2009). MHC Class I-Restricted Human Melanoma Epitope Specific TCR Engineered Human CD4 T Cells Exhibit Anti-Tumor Effector Function, Proliferate upon Cognate Stimulation, Amplify CD8+CTL Generation, and Mitigate Inducible T Regulatory Cell (iTreg) Activities in Human Melanoma, in vitro. Clinical Immunology, 131, S39.
18. Chhabra, A., Yang, L., Wang, P., et al. (2008). CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. Journal Of Immunology, 181(2), 1063-1070.
19. Chhabra, A., Chakraborty, N. G., & Mukherji, B. (2008). Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-127-35. Clinical Immunology, 126(3), 251-259.
20. Hegde, U., Chhabra, A., Chattopadhyay, S., et al. (2008). Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes. Pathobiology, 75(3), 200-208.

Profile Details
https://molecularmedicine.conferenceseries.com/speaker/2015/arvind-chhabra-university-of-connecticut-health-center-usa
https://loop.frontiersin.org/people/154237/overview

WOS ResearcherID: AAG-3530-2020